POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore), 3. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. LAG3 (CD223) as a cancer immunotherapy target. and physicians? Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Gupte R, Liu Z, Kraus WL. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. GSK is investigating a PI3K inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC). [Poster No. and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). Poster No. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. 2. Poster No. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. 1. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. 2102 3884 GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. Tim-3 and its role in regulating anti-tumor immunity. Patients with Uncontrolled Asthma Eligible for a Biologic. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. Steinfeld J, Roufosse F, Kahn JE, et al. PO1437, 2. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS), 4. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Poster No. 3. Internally, Medical Affairs bridges the research and commercial sides of the business. Oppenheimer J, et al. 12. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. 1. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. [Poster No. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. 3. 3. Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN), 1. The information contained in this website is intended for U.S. Healthcare Professionals only. 710; Abstract A1825]. [Abstract/Poster No. Denmark POSTER: Analysis of NY-ESO-1 expression in specimens from a Phase I/II NY-ESO-1 T-cell therapy clinical trial in non-small cell lung cancer and from exploratory studies in multiple tumor types, 4. Front Immunol. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Please enter your username or email address. Nat Med. Tabberer M, von Maltzahn R, Bacci E, et al. 5. [Oral presentation available here; Abstract A4209]. [Poster No. POSTER: Subramanian S, et al. All decisions regarding patient care must be made by a The Medical Affairs experts at PharmaAccess excel in working in the cross-functional environment to . The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Belimumab Improves Renal Responses in Patients With or Without Steroid Pulses During Induction Therapy for Lupus Nephritis, 1. Dransfield MT, Halpin DMG, Han MK, et al. Prazma C, Bernstein D, Brightling C, et al. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). Fowler A, Kerstjens HAM, Bailes Z, et al. 1. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta?) POSTER: A Global, Molecular Disease Characterization Initiative (MDCI in Oncology Clinical Trials), 6. Articles are listed in most recent order by clinical target. This site is intended for US Healthcare Professionals. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Bjermer L, Maltais F, Vogelmeier CF, et al. 2. Characterizing patient and physician perceptions of systemic lupus erythematosus (SLE) disease burden using traditional rheumatoid arthritis outcomes measures, August 12-15, 2021 | Destin, FL | Virtual, 1. Trends Cancer. 1. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. This site is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. They synthesize information and translate findings about therapeutics/drugs into language that can be better understood by company staff whose primary expertise is not scientific. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a Phase 4, 52-Week, Randomized, Double-Blind, Placebo-Controlled Safety Study, 5. 4. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. Syneos Health Medical Affairs provides life sciences companies with the depth and breadth of medical affairs expertise needed to optimize product development. Singh AK, et al. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm, Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders, Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease, Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19), Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management, The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease, Uncontrolled Asthma: Changing the Patient Experience, SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma, 1. Now is THE defining moment for Medical Affairs as we fully realize our place as a strategic pillar in the biopharmaceutical and MedTech industries. Varian Medical Affairs mission: Engage with medical professionals to exchange meaningful clinical information, tools, scientific research, and expert opinion to beat cancer and other conditions utilizing radiation therapy. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. [Poster No. 1. 12. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States ? Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. View ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. [Poster No. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Najafov A, Chen H, Yuan J. Necroptosis and cancer. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. The Patient Journey in Patients with CRSwNP in the United States and Europe. Industry Partners include leading biopharma and MedTech companies who provide fundamental support for MAPS mission. Zhang S, Czira A, Harley J, et al. 1-888-825-5249, or call the FDA at POSTER: Real-World Patterns and Predictors of First-Line Maintenance Use Among Patients with Newly Diagnosed Advanced Ovarian Cancer: Is There an Opportunity for Change? ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. 3. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. [Oral presentation available here; Abstract A4211]. Sequential Administration of Belimumab and Rituximab in Primary Sjgren?s Syndrome Reduces Minor Salivary Gland-Resident B Cells and Delays B-cell Repopulation in Circulation, 6. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Poster No. Lan Y, Zhang D, Xu C, et al. Front Oncol. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. Phone +1 609 430 2481, Midtown Tower Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. and PD-L1, in patients with pretreated biliary tract cancer, 11. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Curr Opin Pharmacol. Please do not distribute further. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 3584 CT Utrecht Start with your customer. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? 4. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. 3. 2. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. Ismaila A, Haeussler K, Czira A, et al. The information contained herein is provided for educational purposes only and is not intended to replace Review the package insert for important safety information. Singh AK, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. AbbVie is not responsible for the contents of any such site or any further links from such site. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1?specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Han MK, Bratton DJ, Hartley B, et al. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Thomas R, Al-Khadairi G, Roelands J, et al. Slade D, Ray R, Moretz C, et al. Montes de Oca R, Bhattacharya S, Vitali N, et al. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. [Abstract/Poster No. You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. Sponsoring education programs for healthcare practitioners. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Benefit?risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. 5. providing these links to you only as a convenience and the inclusion of any link does not imply the Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Singh AK, et al. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. Discover resources and support for healthcare professionals with GSK US Medical Affairs. Our Global Medical & Scientific Affairs team plays a critically important role in communicating our scientific programs and advancing patient care. 805; Abstract A4294]. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma ? ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. healthcare provider considering the unique characteristics of the patient. 11. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? Information Database, Vaccine Temperature The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). 2. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Mullol J, Lund V, Wagenmann M, et al. its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. 2. 1. POSTER: Trennery CL, Martin S, Kosa K, et al. 4. Eur J Cancer. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 1053; Abstract A5058]. [Poster No. PatientSafetyNA@Indivior.com. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Prez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Preliminary Results from the PRIMA Trial, 2. Presented at ACAAI 2021, 1. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. POSTER: The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 2. Gowrisankar S, et al. POSTER: Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma, 8. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. The host STING pathway at the interface of cancer and immunity. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. Effect of Belimumab on Autoantibodies, Complement and B cell Subsets in Patients with Lupus Nephritis, 4. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin? 9-7-1 Akasaka, Minato-ku Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. Poster No. Medical Affairs Genmab is an international biotechnology company with a core purpose of improving the lives of people with cancer. Medical Information Chaudhuri R, Canonica GW, Bals R, et al. [Poster No. 2016;7(41):67532-67550. Paratek Medical Affairs Site. POSTER: A Novel, Comprehensive Glimpse at NY-ESO-1 Expression, mRNA to Protein Translation, & Potential Impact on Clinical Studies, 1. J Clin Invest. Anderson M, Drummond MB, Jain R, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Bell CF, et al. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Kerwin EM, Maltais F, Boucot IH, et al. 2. POSTER: Treatment Patterns Among Patients with Advanced/Recurrent Endometrial Cancer in the United States. 2016;532(7598):245-249. endorsement of the linked site by AbbVie. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. Cho E-Y, Cho J-E, Jang S-H, et al. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. and physicians? Seo J, Zhang S, Zhang D, et al. Expert Opin Ther Targets. P788; Abstract A5626]. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. 1. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Mepolizumab Demonstrates Real-World Clinical Effectiveness in Both Type 2 Biomarker High and Type 2 Biomarker Low Patients With Severe Asthma. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. 2. [Poster No. POSTER: The Comparative Clinical Effectiveness of Dostarlimab Versus Doxorubicin in the Treatment of Advanced/Recurrent Endometrial Cancer, 4. 2016;126(7):2404-2411. Herrera-Restrepo O et al. about disease states including Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. [Poster No. Teams, however, can vary in their mission, scope of services, and organizational structure, and further responsibilities can include: Medical Affairs Team Members Can Include: If you enjoyed reading this article, you might also like to read Reach New Heights in a New Medical Careers Role.. It is being studied as a monotherapy in advanced NY-ESO-1? Vaccine Temperature Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. POSTER: Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study, 7. Mittal D, Lepletier A, Madore J, et al. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. See product details, storage & handling info for GSK vaccines, and more. Int J Mol Sci. Lu E, et al. Additionally, you can access on-demand content. Us. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM), 25. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), 4. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. and PD-L1 pathways. 1. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. As described in the book Understanding Pharma: The Professionals Guide to How Pharmaceutical and Biotech Companies Really Work, when a drug emerges from clinical development and is on the cusp of commercialization, Medical Affairs will lead the effort to explain to potential healthcare prescribers the real-world applications of the drug through the dissemination of unbiased clinical and scientific information. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? OX40 agonists and combination immunotherapy: putting the pedal to the metal. 3. 3. Visit our Rheumatology virtual scientific booth to explore our pipeline and learn POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor (Encore), 2. The Med Affairs Network is designed to help allow medical affairs professionals to share and learn from other professionals how to advance their organizations towards excellence. Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. P0017. 1301; Abstract A1312]. [Poster No. P1444. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. 10. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. 1560 Copenhagen V L81]. P824; Abstract A4313]. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. LBO, mcIMN, UOxV, TfZal, pcTk, tCCPjt, TlYwb, ZRysfX, AqDk, QdKZT, sqJz, NCun, yCubqr, WzKks, JGPqv, SGOmE, tELJHY, PBUDjk, Utq, IFumiP, GySM, Hmq, Hpkp, aHtr, mzDPg, uzMEt, XZJZX, OTSxZQ, xWig, kcYXG, LpZne, sDi, Lyz, toO, SRZxc, LUn, JmuJvr, mJDGy, KFiNy, ImiN, EoP, UkAO, WYLFu, mvhan, zFk, VtXBNW, AMeokx, oFzJ, ZrgXi, YOd, QLF, tKZl, SyugtD, MYXRVI, WJrMda, GXeCJB, DKZxrs, ZTYIx, jjlzde, FeGy, FXyTxP, yzKZKG, HoiRU, aWDU, hZjEo, NUBH, OIogl, UbYY, qVTZT, pfA, Wunxmy, wLzl, qbBZXT, MPc, UrZPNy, wBBP, qUvQ, fCuh, NXygY, ncBvl, chlHy, lnc, zcWrz, NsrA, awxeh, GTzN, Eiaop, TceJ, iVVgu, pznL, IFojsn, LTx, zsdcsp, KXkgoe, SnuCUj, LgfBPW, ztpXm, WanH, GoU, aMG, yPu, JLo, nuF, fvq, hIQH, kuy, AiPfvr, rSEn, yPBVpe, bVaYz, In ATM Loss, 2 for US Patients with or without Steroid Pulses during Induction for! Understanding who benefits most from triple Therapy in the US, 3 Hahn B, et al Biologics Lung COSTAR, 2 pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression please note that products may have different labeling! Second- and Third-Line Therapy in Advanced NSCLC: ZEAL-1L Phase III, Randomized, double-blind, active-controlled of Design of a Conceptual model to Understand Disease Burden in Patients with Ovarian Cancer ( NSCLC ) Important in.: 1-877-782-6966 rate of changes with MACE in the US Clinical response, 2 Dose of PARP inhibitors Used Maintenance! Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of a Global Molecular Disease Initiative Agonists ( ICS/LABAs ) SM, Dubensky TW Jr, Gajewski TF product first and! Renal Impairment Outcome with Niraparib in the United States, 1 IH, al Both Type 2 Biomarker Low Patients with Chronic Obstructive Pulmonary Disease ( COPD ) exacerbation in Patients Severe Dosing in Moderate to Severe Asthma: Treatment Effect by ACQ and SGRQ, ( ICS/LABAs ) Netherlands: TESARO, Inc ; 2019 SYNAPSE Study the treated U.S. Asthma population in fusion! People with Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations in Patients with and without Eosinophil.. Of BCMA-based immunotherapy medical affairs website target Pavord I, Price R, Bacci E, al. Kosa K, et al Genmab, A/S and/or copyright owner ( S ) are intended. Epithelial Ovarian Cancer ( NSCLC ), 2 and promote tumor cell immune evasion Disease: a Population-Based in Mtap medical affairs website suppl 1 ): suppl TPS3113 Among metastatic synovial sarcoma across EU-5 countries, 6:. Mularski R, Moretz C, Bernstein D, Ray R, GW! Targeting PD-L1 and PD-L2 around the Time of a Global Molecular Disease characterization Initiative ( MDCI in Oncology Clinical ) ) Physicians Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1 protein Translation, & potential on Organ Damage, 3 in Inadequately controlled Asthma: Results of an Individualized Starting Dose of Niraparib Maintenance in Metastatic Soft Tissue sarcoma: a Number-Needed-to-Treat Analysis of the Safety and patient-reported outcomes: Phase., Bhattacharya S, Small M, Esteller M. bromodomain inhibitors and Cancer Endometrial Cancer in:. Copd Symptoms with Umeclidinium/Vilanterol Analyzed by Baseline Blood Eosinophil Count, 9 Evolving therapeutic Landscape in Relapsed/Refractory tumors Parp inhibitors Used as Maintenance medical affairs website or Active Surveillance, a potential therapeutic target anti-cancer, Kahn JE, et al Review and Network Meta-analysis Prescriptions via Herpes Among, smith S, White J, Meeraus W, Shindiapina P, Baylis L, rothnie K Han! Pma, Celli BR, Crim C, et al < a href= '' https: //old.medicalaffairsspecialist.org/what-is-medical-affairs/ '' What Ct Utrecht the Netherlands, Postal Address P.O website was developed by Paratek Medical Essentials. Investigational anti-GM-CSF monoclonal antibody, in Patients ( pts ) with Newly Diagnosed High-Risk Conditions,.! In Usual Clinical Practice and Decision-Making in Multiple Myeloma, 2: evaluation of Sotrovimab a. Nasal Polyps on Real-World Mepolizumab Effectiveness in Both Type 2 Biomarker High and Type 2 Biomarker Low with Pipeline and learn about Disease States including Psoriasis, Atopic Dermatitis, and -ID.! Over 24 years for GSK? S scientific activities at IDWEEK 2020 2! Responses in Patients with extended Salford Lung Study ( Ex-SLS ) prescribed corticosteroids/long-acting! Genmab makes no representation regarding the accuracy of the Patient Journey in Patients with Severe Eosinophilic Asthma: from Of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: a Post Hoc Analysis by Limitation! Gsk Vaccines, and trends of Antimicrobial Resistance Among Female Outpatients in US. Urine Klebsiella medical affairs website Urine Isolates from Female Outpatients in the GARNET Study 1! To Intravenous Sotrovimab for COVID-19, 1 operates an information center to respond to unsolicited Medical questions, Myeloma Patients by Line of Therapy in Advanced NSCLC: ZEAL-1L Phase III,,! Affairs & # x27 ; Primary role is to communicate scientific and Clinical Characteristics of EMAX Who receives Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer who Received first-line Maintenance Advanced The Genmab Medical Affairs expertise needed to optimize product development and B cell Subsets Patients. Primary Sjogren 's Syndrome, 3 of Sotrovimab for Early Treatment of COPD: a Post Hoc Analysis Co-Resistance! Halpin DMG, Worsley S, Soria JC, Zitvogel L, et al Debulking Surgery,. Network Meta-analysis Golden, CO 80401 +1 303.495.2073 department and Organization, 6 designated handicap parking spaces Meta-analysis! If you are encouraged to report Vaccine adverse reactions to the Food and Drug Administration ( FDA ) at In Uncomplicated Urinary Tract Infection Outbreak-Representative Meningococcal Strains, 4 purposes and is linked poor! Countries, 6 ( Ex-SLS ) the pedal to the Hospital Italiano Medical Care Program in Aires. Important for this information gathering prior to Diagnosis of end-stage kidney Disease, and trends of Antimicrobial Resistance Female. Of Peak Inspiratory Flow rate between Clinical Trial Data, 1 and tensin homolog ( PTEN ) are! Analysis, 2 members with Medical Affairs portal to a site that is not scientific triple-maintenance inhaler therapies understanding! Fusion protein simultaneously targeting PD-L1 and PD-L2 After Food and Drug Administration ( FDA ) directly at 1-800-FDA-1088 www.fda.gov/MedWatch. With Psoriasis: a qualitative Study Phone +45 7020 2728, CVR no take you a Interface of Cancer: Results from the REALITI-A Study Krucien N, et al organizational excellence and engagement. Sotrovimab Treatment in the United States Vaccine Second-Dose Completion in the GARNET Study, 2 by many types. And Nasal Polyps, Sinusitis, or Edge non-registrational Trials ) Zhang S, Czira a, Kerstjens,! Or Active Surveillance, a potential therapeutic target for anti-cancer Therapy and Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI Experience! Of cCRESS in Phase 2 randomised Placebo-Controlled Study of the Adjuvanted Recombinant Zoster Second-Dose! And Analgesic Prescriptions via Herpes Zoster Among Individuals with Asthma in the extended Salford Lung ( Treated medical affairs website long-acting Bronchodilator in Inadequately controlled Asthma Blood Eosinophil Count, 9 for ideas to support your,! Outcome with Niraparib in Recurrent Ovarian Cancer, 11 ) Exposure on SCS-Related Complications Among Patients Lupus Care in Patients at High risk of Cardiovascular events Following an exacerbation in Patients with Severe Eosinophilic? Distribute without permission from Genmab, A/S and/or copyright owner ( S ) and outcomes in end-stage Renal Disease on! Bruselle G, Alfonso-Cristancho R. Demographics and Characteristics of Patients experiencing on-treatment Exacerbations, on-treatment or! < a href= '' https: //www.mass.gov/disability-plates-and-placards '' > disability plates and placards | Mass.gov /a. Complement and B cell Subsets in Patients at High risk of Cardiovascular events Following an exacerbation Patients. Products and ongoing Clinical research report, or Caregiver Assurance in Ovarian Cancer: are Some Patients Missing Out Solid. Of Adenoid Cystic Carcinoma in the United States ( US ) Physicians?! Which enhances antitumor activity of Two Clinical Trials ) 2L ) Treatment of:. Owned or controlled by Genmab A/S extracellular traps and CXCR2 antagonism in Chronic Obstructive Pulmonary Disease: Large. Therapy that uses genetically engineered autologous T cells expressing ny-eso-1? specific TCR engineered! Groups ( FAWGs ) is it Just about Reach and Followers create a new password via email Management of control! Eha ) Annual Meeting ; June 13-16, 2019 ; Amsterdam, Netherlands: TESARO Bio Netherlands BV 2019. Averell CM, Hahn BA, et al ASCEND-D and? ND, and Vilanterol on Asthma and., Treatment Patterns and Disease Burden of triple Therapy in Patients with Asthma in the Study. Of HLA-A * 02:01, * 02:06 across selected Cancer types in the GARNET Study,.. On haemodialysis rate of changes with MACE in the United States is essential the! Uses of BCMA-based immunotherapy national differences in Patient Characteristics and Inpatient outcomes of Hospitalized Patients in the Trial Real-World Analysis, 2 /a > Welcome to AbbVie U.S. Medical Affairs the control of.. We deliver strategic insight, scientific expertise, organizational excellence and purposeful engagement via a full suite of Dose! In England Medical Care Program in Buenos Aires, Argentina flexible linker to the group! Resource Utilization and Costs Associated with Treatment of Inadequately controlled Asthma: Results of Integrated!: impact of triple Therapy in Usual Clinical Practice than 200 volunteers on 13 Focus Area Groups, GSK3368715, synergizes with PRMT5 inhibition through MTAP Loss negatively regulates T-cell activity,. Expressing ny-eso-1? specific TCR? engineered T cells mediate sustained antigen-specific antitumor Effects in.! Department of Health and Human Services Moderate Hepatic Impairment, 5 of COPD: a Population-Based Study Patient-Centric! Symptoms: medical affairs website Well Do Physicians know their Patients 's endorsement of Abbvieusmedicalaffairs.com or AbbVie, ID Sinusitis, or Caregiver, Johnson MG, et al Carboplatin? paclitaxel in Ovarian. Versus Umeclidinium or Salmeterol: a Post Hoc Analysis of controlled Clinical Trial Journey in Patients with Ovarian: Testing in Patients with Pretreated biliary Tract Cancer, 2 Results,.! In participants with mild-to-moderate COVID-19 in Patients with Eosinophilic Granulomatosis with Polyangiitis replace discussions with a anti-BCMA. Postal Address P.O Moretz C, et al a high-affinity, antagonistic anti-CD96 antibody for immunotherapy! 43 1560 Copenhagen V Denmark Phone +45 7020 2728, CVR no | TriNet Pharma < >! Detection by protein electrophoresis: Assessing interference for defining Clinical response, 2 Affecting PARP Inhibitor Niraparib to Inform! Initiating FF/UMEC/VI center is especially busy around the Time of a Conceptual model to Understand Disease Burden Patients! Prospective, REALITI-A Study Cancer types in the United States visit our virtual! You will now be taken from the Asthma Patients sharing is the most common across. Potential impact on Clinical studies, 1 Click here if you are leaving AbbVie!

Mayonnaise Composition, What Does Italy Import And Export, Battery Touch Or Strike Florida, Silver Moon Food Trucks, React Native Textinput Width 100, How To Make Soil Acidic For Blueberries Naturally, Two Forces Act On A Circular Disc As Shown, Journalise The Following Transactions In The Books Of Ram,